Ig therapy is generally delivered in one of two ways. Intravenous Ig therapy, or IVIg, is administered into the vein by a medical professional. Patients with PI typically receive IVIg once every 3-4 weeks. Maintenance IVIG therapy for CIDP is often administered once every 3 weeks.
Subcutaneous Ig therapy, or SCIg, is infused in the fatty layer under the skin (not in a vein). It uses a relatively small needle and an infusion pump. With proper training, most patients can self-infuse SCIg (or be assisted by a caregiver). Most SCIg products are infused weekly, as Hizentra is for CIDP, but for those with PI, Hizentra provides the option to infuse as often as daily or up to once every 2 weeks. Talk with your healthcare provider about the dosing option that's right for you.
As a 20% Ig therapy, Hizentra has the highest concentration of immunoglobulin available in a SCIg treatment, so you can receive the IgG your body needs while infusing a low volume, which potentially results in fewer needlesticks. Hizentra was specifically designed to deliver Ig levels in half the volume of 10% Ig products,* regardless of which dosing schedule you and your healthcare provider choose.
*Based on an equivalent dose in grams.
Hizentra can be stored at room temperature (up to 77°F [25°C]) for its entire shelf life, up to 30 months, as indicated by the expiration date printed on the outer carton and vial label. This means you don't have to worry about refrigerating Hizentra when you are on the go.
That depends on the schedule that you and your doctor decide is best for you. Hizentra gives you continuous protection with weekly dosing for CIDP and dosing options that range from once a day to once every 2 weeks for PI.
You and your doctor can choose your Hizentra dosing treatment plan based on:
The amount of Hizentra you infuse per month will not change, regardless of how often you infuse.
How long each infusion takes may vary based on a number of factors, including how often you infuse, the number of infusion sites you use, your infusion rate, and other factors. You and your doctor can decide what is best for you.
Please remember that infusing more or less often than once per week is recommended for PI patients, not CIDP patients.
The most common side effects demonstrated in the clinical trials for Hizentra were local infusion-site reactions, headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain (upper), migraine, arthralgia, pain, fall, and nasopharyngitis. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.
Most patients/caregivers can be trained to infuse. However, self-administration should be done only after you go through training and perform a successful demonstration in front of a healthcare professional. You can always ask your healthcare professional questions about self-administration, especially if you need a refresher or if your infusion regimen has recently changed.
When you sign up for Premier StartSM, you may be able to receive a 4-week supply of Hizentra and infusion equipment at no cost to you, plus free at-home visits by a trained nurse to help you learn to infuse.
Yes. Partnering with one's healthcare provider is necessary for patients receiving Ig treatment. Regular healthcare provider visits are an important part of your therapy program. At each visit, your healthcare provider will evaluate your dose and your response to treatment and address any concerns you may have. It's important to bring your Hizentra therapy journal or send infusion records via the MyHizentra® Infusion Manager app to share with your healthcare provider.
Talk with your healthcare provider about which option is best for you. For CIDP, the recommended dosing schedule is weekly. For PI, several dosing schedules (from daily to once every 2 weeks) are available, and your doctor will work with you to find the dosing schedule that works best for you.
A Hizentra dose may be infused into as many as 8 infusion sites simultaneously. In clinical trials, PI patients generally used 4 or fewer infusion sites per infusion, while CIDP patients most often used 4. The number and location of infusion sites depend on the volume of the total dose. Infusion sites should be at least 2 inches apart. Change the actual site of infusion with each administration. New sites should be at least 1 inch from previous site. Recommended infusion sites include the thighs, upper arms, stomach, and hips.
The median infusion time based on the clinical trials was about 1.5–2 hours for PI, and about 1 hour for CIDP. Your infusion time may be shorter or longer, depending on the dose and frequency your healthcare provider has prescribed for you. Your experience may vary depending on a number of factors, including number of infusion sites, tubing, and how well you tolerate the treatment.
For PI patients, your initial rate should not exceed 15 mL/hour/site, but can then be ramped up to as much as 25 mL/hour/site depending on how you feel.
For CIDP patients, your initial rate should not exceed 20 mL/hour/site, but can then be ramped up to as much as 50 mL/hour/site depending on how you feel.
We are working to have Hizentra covered by as many health insurance formularies as possible. IgIQ can also help you by doing a full benefits investigation to help you understand your options and how much they cost, identify managed care reimbursement opportunities, and talk to you about financial assistance if you're uninsured.
The cost of any treatment, including Hizentra, depends on a number of factors, including insurance status and the insurer’s co-pay/coinsurance policy. The actual out-of-pocket cost to a patient will depend on their individual prescription and medical coverage.
For those who cannot afford their treatment, CSL Behring is committed to providing appropriate resources to ensure patients can begin and/or remain on their therapy. These include:
CSL Behring AssuranceSM–The CSL Behring Assurance Program may be able to help you continue to receive treatment even if you experience a lapse in third-party private health insurance. Eligible patients earn points for Hizentra that you can use to secure medicine should you have a lapse in your third-party private health insurance. It is free and features easy enrollment and participation.
Hizentra Co-Pay Relief Program The Hizentra Co-Pay Relief program helps people who are eligible afford their therapy by helping with monthly out-of-pocket expenses for Hizentra (up to $5,000 for one year, with no monthly cap).*
*This program applies to product costs only; contact IgIQ to learn more.
CSL Behring Patient Assistance Program–The CSL Behring Patient Assistance Program may help if you are uninsured or underinsured, or otherwise can't afford SCIg therapy. If you qualify, you may receive up to a 3-month supply of SCIg therapy. At the end of 3 months, your eligibility is reevaluated for continued participation. If you have an emergency need for SCIg therapy, it will be addressed under a separate process when the call is received within 24 hours of the emergency.
Other terms and conditions apply. For more information, call the IgIQ Resource Center, CSL Behring's single source for information about immunoglobulin therapies, at 1-877-355-IGIQ (4447), Monday‑Friday, 8 AM to 8 PM ET
If you and your doctor have decided you’re ready to start Hizentra, you may be able to get a 1-month supply of medicine, infusion equipment, and in-home nurse training for free.
To apply for this program, ask your doctor to call IgIQ to see if you are eligible. For more information, call 1-877-355-IGIQ (4447), Monday‑Friday, 8 AM to 8 PM ET.
If you are a Hizentra patient or caregiver, you can sign up for Voice2Voice, a unique program from CSL Behring that provides the opportunity for patients and caregivers to connect and share their experience firsthand.*
*Voice2Voice advocates are not healthcare professionals or medical experts. For medical questions, please contact your physician. Voice2Voice advocates are compensated by CSL Behring LLC for their time and/or expenses.
Contact IgIQ, who will conduct a full benefits investigation and assist in resolving the problem.
Patients with PI should visit the Immune Deficiency Foundations (IDF) website, a global patient organization for patients with PI. Patients with CIDP should visit GBS/CIDP Foundation website, a global patient organization for patients with CIDP.